Therapeutic Leukapheresis for Acute Lymphoblastic Leukemia with Severe Hyperleukocytosis in a Six-Week-Old Infant (4.7 kg).
- Author:
Ji Yoon BYUN
1
;
Kyung Mi SHIN
;
Sung Chul WON
;
Chuhl Joo LYU
;
Hyun Sook LIM
;
Hyun Ok KIM
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea. cj@yumc.yonsei.ac.kr
- Publication Type:Case Report
- Keywords:
Therapeutic leukapheresis;
Acute lymphoblastic leukemia;
Hyperleukocytosis;
Infant
- MeSH:
Central Venous Catheters;
Drug Therapy;
Female;
Femoral Vein;
Humans;
Infant*;
Leukapheresis*;
Leukocytes;
Leukostasis;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*;
Vomiting
- From:Korean Journal of Pediatric Hematology-Oncology
2002;9(2):250-254
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We report a 4.7 kg infant who received a therapeutic leukapheresis as an immediate treatment for acute lymphoblastic leukemia with severe hyperleukocytosis. By decreasing the number of circulating white blood cells, therapeutic leukapheresis helps prevent the risks of hyperviscosity and cerebrovascular and pulmonary leukostasis. In addition, it potentially reduces metabolic and renal complications associated with rapid cell lysis when applied before chemotherapy. This six-week-old female presented with vomiting for 15 days. Initial WBC count was 1,532,800/muL. After placement of 4 french two-lumen central venous catheter in both femoral vein, the CS 3000 plus was primed with 250 mL of paternal whole blood mixed with 150 mL of normal saline. After therapeutic leukapheresis, the CBC showed WBC count of 560,000/muL. Our successful experience in performing this procedure suggests that therapeutic leukapheresis be a feasible treatment even for very young infants with hyperleukocytosis.
